September 6, 2024 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS), Enhancing Oncology Model (EOM), and Advance Care Planning (ACP).
MIPS Quality Measures Dashboard
Update to MIPS #134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan eCQM & CQM/Registry versions
When users select the follow-up plan option “Under current care of a practitioner who is qualified to diagnose and treat depression” for a patient with a positive depression screening, it will now be considered as “Numerator Met”. This update will include previously documented instances of this selection.
Additional MIPS Measure Updates
The dashboard has been updated to reflect the below refinement(s) for:
| Measure | Update | Practice Impact |
|---|---|---|
| MIPS #144: Oncology: Medical and Radiation – Plan of Care for Pain | Removed ICD-10 D48.1 and added D48.19 | Practices will not notice numerator or denominator changes. |
| MIPS #453: Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life | Removed ICD-10 D48.1 and added D48.19 | Practices will not notice numerator or denominator changes. |
| MIPS #457: Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days | Removed ICD-10 D48.1 and added D48.19 | Practices will not notice numerator or denominator changes. |
EOM Quality Measures Dashboard
When users select the follow-up plan option “Under current care of a practitioner who is qualified to diagnose and treat depression” for a patient with a positive depression screening, it will now be considered as “Numerator Met” for EOM-5: Depression Screening. This update will include previously documented instances of this selection.
Advance Care Planning Performance Dashboard
Starting Monday, Sept. 9, 2024, you can view the final refreshed data from Q2 2024 using the Time Period drop-down on the Advance Care Planning Performance and Advance Care Planning Activities dashboards.
Status of Dashboard Updates for 2024
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #047 | Advance Care Plan |
| #104 | Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer |
| #128 | BMI (This measure is no longer a MIPS Traditional Measure) |
| #130 | Current Medications |
| #134 eCQM | Preventive Care Screening: Screening for Depression and Follow-Up Plan |
| #134 CQM / Registry | Preventive Care Screening: Screening for Depression and Follow-Up Plan |
| #143 | Pain Intensity Quantified |
| #144 | Pain Care Plan |
| #374 | Closing the Referral Loop |
| #450 | Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adjuvant Chemotherapy |
| #451 | RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Received Anti-EGFT Monoclonal Antibody Therapy |
| #452 | Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene MutationSpared Treatment with Anti-EGFR Monoclonal Antibodies |
| #453 | Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (Inverse Measure) |
| #457 | Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (Inverse Measure) |
| #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| PIMSH #1 | Advance Care Planning in Stage 4 Disease |
| PIMSH #2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH #4 | Patient-Reported Pain Improvement |
| PIMSH #9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH #10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #13 | Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy (EGFR, BRAF, ROS1, ALK, PD-L1) |
| PIMSH #15 | Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
| PIMSH #16 | Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |